555TiP A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors

Calvo, Emiliano; Hollebecque, Antoine; Dowlati, Afshin; Piha-Paul, S. A.; Galvão, Violeta Régnier; Lopez, Juanita; Sehgal, Kartik; Bockorny, Bruno; Braiteh, Fadi; Peters, Solveig; Sanborn, Rachel E.; Zhou, Pei; Nazarenko, Natalya; Patnaik, Amita

doi:10.1016/j.annonc.2021.08.1077

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40 Other ADCs being investigated in early phase clinical trials in UC are SGN-B6A, DS-7300 and camidanlumab tesirine targeting integrin β6, B7-H3 transmembrane glycoprotein and anti-CD25. [41][42][43] Role of Human Trophoblast Cell Surface Antigen 2…”

Section: Use Of Adcs In Ucmentioning

confidence: 99%

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan

Fontes¹,

Almeida²,

Cavalin³

et al. 2022

OTT

View full text Add to dashboard Cite

Urothelial carcinoma is the second most frequent genitourinary malignancy. Despite the poor prognosis, new treatment options have emerged and have expanded the therapeutic landscape for the disease. Although major improvements have been achieved, many patients experience rapid disease progression and low responses in subsequent lines of therapy. Sacituzumab govitecan is an ADC that targets Trop-2, which is highly expressed in urothelial cancers. Promising results in early clinical trials have led to further drug development which confirmed encouraging efficacy. Sacituzumab govitecan has been given accelerated approval in 2021 for patients with locally advanced and metastatic urothelial cancer who previously received a platinum containing chemotherapy and either a programmed death receptor-1 or programmed death ligand inhibitor. The results are promising, with encouraging efficacy and safety, however responses are not universal. There is a growing comprehension of mechanisms of resistance and predictive biomarkers that are crucial to improving outcomes. In this review, we summarize the current knowledge on antibody-drug conjugates and the clinical findings that led to the approval of Sacituzumab govitecan and discuss the therapeutic potential of new combinations, mechanisms of resistance and predictive biomarkers.

show abstract